AIV Logo AIV Assistant

Loading...

 Logo BioLineRx Ltd. - BLRX Open BioLineRx Ltd. in new tab

3.45
EPS
-6.00
P/B
465.00
ROE
-0.46
Beta
0.91

3.4500

3.450

Daily: -1.43%
Key Metrics

Earnings date: Nov. 24, 2025

EPS: -6.00

Book Value: 0.01

Price to Book: 465.00

Debt/Equity: 62.79

% Insiders: 0.040%

Growth

Revenue Growth: -0.94%

Estimates

Forward P/E: -16.91

Forward EPS: -0.22

 Logo About BioLineRx Ltd. - (BLRX)

Country: Israel

Sector: Health Care

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

Dividends

Historical Split Corporate Actions

Trades
My Trades
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion